Hou, Y., & Wu, B. (2020). Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis. Cancer Commun (Lond).
Citación estilo ChicagoHou, Yanli, and Bin Wu. "Atezolizumab Plus Bevacizumab Versus Sorafenib As First‐line Treatment for Unresectable Hepatocellular Carcinoma: A Cost‐effectiveness Analysis." Cancer Commun (Lond) 2020.
Cita MLAHou, Yanli, and Bin Wu. "Atezolizumab Plus Bevacizumab Versus Sorafenib As First‐line Treatment for Unresectable Hepatocellular Carcinoma: A Cost‐effectiveness Analysis." Cancer Commun (Lond) 2020.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.